FIELD: biotechnology.
SUBSTANCE: following is proposed: a version of hyaluronidase PH20 or a fragment thereof that has hyaluronidase activity including the replacement, deletion or insertion of an amino acid residue in at least one position in the version containing the amino acid sequence SEQ ID NO: 3. Also the following is proposed: a composition for the treatment of cancer containing a version of PH20 or a fragment thereof, a nucleic acid encoding a version of hyaluronidase PH20 or a fragment thereof, a recombinant expression vector containing the said nucleic acid, a host cell transformed by the said vector, and a method of producing the version of hyaluronidase PH20 or its fragment.
EFFECT: PH20 version or a fragment thereof has improved thermostability and human hyaluronidase enzymatic activity.
13 cl, 4 dwg, 8 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION, INCLUDING A PH20 VARIANT OF HUMAN HYALURONIDASE, AND A MEDICINAL PRODUCT FOR SUBCUTANEOUS ADMINISTRATION | 2020 |
|
RU2810952C2 |
| NEW VERSIONS OF HYALURONIDASE AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2019 |
|
RU2766680C1 |
| ANTIBODIES AGAINST CXCR2 AND THEIR USE | 2019 |
|
RU2807067C2 |
| POLYPEPTIDE COMPRISING ANTIGEN-BINDING DOMAIN AND TRANSPORT SEGMENT | 2018 |
|
RU2815452C2 |
| POLYPEPTIDES RECRUITING T-CELLS, CAPABLE OF BINDING CD123 AND ALPHA/BETA TCR | 2017 |
|
RU2775063C2 |
| IMPROVED SINGLE VARIABLE IMMUNOGLOBULIN DOMAINS BINDING TO SERUM ALBUMIN | 2017 |
|
RU2765384C2 |
| LIGAND-BINDING MOLECULE WITH REGULATED LIGAND-BINDING ACTIVITY | 2017 |
|
RU2803067C2 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC-REGION VARIANTS, AND THEIR APPLICATION METHODS | 2016 |
|
RU2789884C2 |
| NEW VARIANT OF L-TYROSINE-EXPORTING PROTEIN AND METHOD OF OBTAINING L-TYROSINE USING IT | 2021 |
|
RU2808831C1 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
